Institutional Cluster

BEAM

Beam Therapeutics Inc.
BULLISH
Impact 5/10
Horizonweeks Processed1mo ago
Institutional cluster: 8 buyers, 2 sellers (bullish)
Actionable Insight ▲ Bullish

The Q2 2026 institutional cluster is directionally bullish but carries significant caveats: the 45-day reporting lag means these positions may already be unwound, and the lack of insider buying (confluence score 21/100, divergent) weakens conviction. Monitor for any Q3 2026 13F filings or insider Form 4 open-market buys to confirm the thesis is still active. Given BEAM's historical T+20 win rate of only 44% and near-zero average alpha, treat this as a modest positive signal rather than a strong buy catalyst.

DirectionBullish
Confidencemedium
Horizonweeks
Latest settled — T+20d
BEAM ▼ -14.32% at T+20d
LONG call ✗ call lost -14.32% · α vs SPY -12.34% · entry $27.10 → $23.22
Next anchor: T+60d in 5w
Latest observation: T+32 +12.66% FF3 residual α
Entry anchored
Aug 15, 2026
via day open
T+1d
-1.96%
call -1.96% · α -1.28%
$26.57
settled 7w ago
T+5d
+4.54%
call +4.54% · α +5.73%
$28.33
settled 6w ago
T+20d
-14.32%
call -14.32% · α -12.34%
$23.22
settled 18d ago
T+60d
—
call — · α —
—
in 5w

Executive Summary

Eight institutional investors accumulated $59.7M in BEAM during Q2 2026, led by Morgan Stanley doubling its stake to $67M, while two smaller sellers trimmed $1.2M. The cluster is dominated by active asset managers with strong conviction (6 DOUBLED positions), but the 45-day reporting lag means positions may have been unwound. Historical calibration shows BEAM reports have a 44% win rate at T+20 with near-zero average alpha, and the score-8 bucket has only a 37% observed up-move rate, warranting a modest impact score despite the bullish signal. No insider open-market buying corroborates the institutional accumulation, weakening the conviction signal per the confluence score of 21/100 (divergent). The cross-filing amplifier (inst-earnings + inst-offering context) supports a slightly elevated score, but the historical underperformance of high-score BEAM calls and the lack of insider buying keep the impact at 5 rather than 6+.

Key Financial Metrics

Direction
accumulating
Buy Value
$80.3M
Sell Value
$2.5M
Net Flow
$58.5M

Institutional Positions

Net institutional flow: $58.5M

▲ Buyers (8)

InstitutionActionChangePosition ValueValue Δ
Morgan StanleyDOUBLED+201%$67.0M$51.5M
CitigroupDOUBLED+107.7%$4.8M$3.2M
First Trust AdvisorsADD+32.4%$6.1M$2.9M
Concurrent Investment AdvisorsDOUBLED+448.7%$2.2M$1.9M

▼ Sellers (2)

InstitutionActionChangePrev ValueValue Δ
Clearstead AdvisorsTRIM-50%$2.9M-$808.4K
Victory Capital ManagementTRIM-65.1%$741.0K-$369.1K

Key Facts

  • 8 institutional buyers accumulated $59.7M in BEAM during Q2 2026, with 6 funds doubling their positions
  • Morgan Stanley was the largest buyer, increasing its stake by 201% to $67M (from $15.4M)
  • Only 2 small sellers trimmed a combined $1.2M, with no full exits
  • No insider open-market buying was detected, and the 13F × Form 4 confluence score is 21/100 (divergent)
  • Historical BEAM reports have a 44% win rate at T+20 with average alpha of +0.18%, and score-8 calls have only a 37% observed up-move rate

Financial Impact

8 institutional buyers added $59.7M in new positions (led by Morgan Stanley's $51.5M increase to $67M), while 2 sellers trimmed $1.2M, for net institutional accumulation of $58.5M

institutional_ownershipfloat_percentage

Risk Factors

  • 45-day 13F reporting lag means Q2 positions may have been unwound by now
  • No insider open-market buying to corroborate institutional accumulation
  • Historical BEAM reports show only 44% win rate at T+20 with near-zero average alpha
  • Score-8 calls in this segment have only 37% observed up-move rate historically
  • Cluster dominated by one large buyer (Morgan Stanley at $67M) — concentration risk if that fund reversed

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
87% bullish (23 analysts)

Investment Themes

Biotech & Drug DiscoveryGenomics & Gene Editing

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-BEAM-2026-Q2
7 reports for BEAM
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +53.81%Mar 25, 2026
Filters
Rows
Reports for BEAM — sortable, filterable
TypeNow
Aug 15, 2026
6w ago
Institutional Cluster
BULLISH ★ 5/10
$27.10 $23.22▼ −14.32%▼ −12.34%—
Jul 2, 2026
13w ago
Insider Cluster
MIXED ★ 5/10
$34.79 $26.49▼ −23.86%▼ −23.44%—
Jul 1, 2026
13w ago
Insider Cluster
BEARISH ★ 4/10
$33.48 $26.02▲ +22.28%▲ +20.10%—
May 12, 2026
20w ago
Press Release
BULLISH ★ 7/10
$31.58 $29.49▼ −6.62%▼ −4.89%—
Apr 17, 2026
24w ago
DEFA14A
NEUTRAL ★ 3/10
$31.19 $26.81▼ −14.04%▼ −18.25%—
Mar 25, 2026
27w ago
Press Release
BULLISH ★ 8/10
$23.12 $30.16▲ +30.45%▲ +22.59%—
Mar 5, 2026
30w ago
8-K
NEUTRAL ★ 4/10
$26.54 $24.23▼ −8.70%▼ −6.66%—
Showing 7 of 7

US Market Status

Market Closed — Opens Mon (65h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 15, 2026